Dealmaking

Women in PE: Call for nominations

We'll consider candidates from all aspects of PE, including dealmaking, fundraising, value creation and more. The deadline is February 13.

Astorg, Charterhouse, Grant Avenue bet on dietary supplements; Vistria, EQT target secondaries market; Last chance for entries to PE Hub's Deal of the Year

Exploring trends and transactions in the dietary supplements space; parsing Vistria‘s debut multi-asset CV transaction and EQT’s entry into the secondaries market with its acquisition of Coller Capital; a reminder: today is the deadline for submissions to PE Hub’s Deal of the Year Awards.

PE goes for dietary supplements: 6 deals

Astorg, Charterhouse and Grant Avenue Capital are among the PE firms investing in the dietary supplements sector.

Carlyle, LDC among PE firms backing mental health M&A; Mid-market style execution setting the tone for 2026 deals, says Aon

PE Hub covered six deals in the mental health sector in the last four months.

'Long-term growth rates' attract PE to mental and behavioral health: 6 deals

Carlyle, LDC and Sheridan Capital are among the PE firms pursuing deals in mental and behavioral healthcare.

Strings attached: navigating legacy with founder and family transitions

Investors need to be nimble in balancing respect for the seller's legacy with the practicalities of operating a business, write Carl Bradshaw and Angus Simpson of law firm Goodwin.

EQT nabs secondaries firm Coller Capital for $3.2bn; Carlyle’s Robert Schmidt points to open IPO window following Medline listing

EQT makes a splash in the secondaries market in buying Coller Capital; a huge IPO deep dive involving Blackstone, Carlyle, and Hellman & Friedman-backed Medline; highlighting Bridgepoint-owned ECP’s sale of three Midwest power plants to a strategic; deal activity in the automotive market increases in 2025.

Medline shows 'the IPO window is open for scaled, high-quality assets'

'Being public gives the company a very attractive cost of capital currency to go and think creatively about what future deals Medline would like to do,' said Carlyle's Robert Schmidt about the largest IPO of 2025.

Sale processes slow amid tariff uncertainty; Goldman Sachs finds opportunity in volatility; Strong growth potential in UK wellness sector, says Shoosmiths

Markets react to signs of relief amid reduced tariff uncertainty.

Oakley hands €640m back to LPs in 2025, extends multi-year liquidity run

The London-headquartered firm held the final close on its sixth flagship fund on €4.5bn last year and has already deployed capital across four deals, partner Rebecca Gibson tells PEI.